BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 10528184)

  • 21. Role of 4-1BB:4-1BB ligand in cancer immunotherapy.
    Cheuk AT; Mufti GJ; Guinn BA
    Cancer Gene Ther; 2004 Mar; 11(3):215-26. PubMed ID: 14671675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma.
    Xu DP; Sauter BV; Huang TG; Meseck M; Woo SL; Chen SH
    Gene Ther; 2005 Oct; 12(20):1526-33. PubMed ID: 15973445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impairment and delay of neutralizing antiviral antibody responses by virus-specific cytotoxic T cells.
    Battegay M; Moskophidis D; Waldner H; Bründler MA; Fung-Leung WP; Mak TW; Hengartner H; Zinkernagel RM
    J Immunol; 1993 Nov; 151(10):5408-15. PubMed ID: 7693811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Virus-specific cytotoxic T cell-mediated lysis of lymphocytes in vitro and in vivo.
    Kyburz D; Speiser DE; Aebischer T; Hengartner H; Zinkernagel RM
    J Immunol; 1993 Jun; 150(11):5051-8. PubMed ID: 7684417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blockade of the 4-1BB (CD137)/4-1BBL and/or CD28/CD80/CD86 costimulatory pathways promotes corneal allograft survival in mice.
    Asai T; Choi BK; Kwon PM; Kim WY; Kim JD; Vinay DS; Gebhardt BM; Kwon BS
    Immunology; 2007 Jul; 121(3):349-58. PubMed ID: 17376197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of the costimulatory receptor CD30 is regulated by both CD28 and cytokines.
    Gilfillan MC; Noel PJ; Podack ER; Reiner SL; Thompson CB
    J Immunol; 1998 Mar; 160(5):2180-7. PubMed ID: 9498756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential role of 4-1BB in T cell activation. Comparison with the costimulatory molecule CD28.
    Hurtado JC; Kim SH; Pollok KE; Lee ZH; Kwon BS
    J Immunol; 1995 Oct; 155(7):3360-7. PubMed ID: 7561030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 4-1BB costimulation is required for protective anti-viral immunity after peptide vaccination.
    Tan JT; Whitmire JK; Murali-Krishna K; Ahmed R; Altman JD; Mittler RS; Sette A; Pearson TC; Larsen CP
    J Immunol; 2000 Mar; 164(5):2320-5. PubMed ID: 10679066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 4-1BB (CD137) signals depend upon CD28 signals in alloimmune responses.
    Lee EA; Kim JE; Seo JH; Kwon BS; Nam SH; Kwon B; Cho HR
    Exp Mol Med; 2006 Dec; 38(6):606-15. PubMed ID: 17202836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peripheral T cells in mice lacking p56lck do not express significant antiviral effector functions.
    Molina TJ; Bachmann MF; Kündig TM; Zinkernagel RM; Mak TW
    J Immunol; 1993 Jul; 151(2):699-706. PubMed ID: 8393038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD2-deficient mice generate virus-specific cytotoxic T lymphocytes upon infection with lymphocytic choriomeningitis virus.
    Evans CF; Rall GF; Killeen N; Littman D; Oldstone MB
    J Immunol; 1993 Dec; 151(11):6259-64. PubMed ID: 7902375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Local IL-4 expression in the lung reduces pulmonary influenza-virus-specific secondary cytotoxic T cell responses.
    Bot A; Holz A; Christen U; Wolfe T; Temann A; Flavell R; von Herrath M
    Virology; 2000 Mar; 269(1):66-77. PubMed ID: 10725199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand.
    Saoulli K; Lee SY; Cannons JL; Yeh WC; Santana A; Goldstein MD; Bangia N; DeBenedette MA; Mak TW; Choi Y; Watts TH
    J Exp Med; 1998 Jun; 187(11):1849-62. PubMed ID: 9607925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of 4-1BB in immune responses.
    Vinay DS; Kwon BS
    Semin Immunol; 1998 Dec; 10(6):481-9. PubMed ID: 9826581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD28 is not required for rejection of unmanipulated syngeneic and autologous tumors.
    Wen T; Kono K; Shahinian A; Kiessling R; Mak TW; Klein G
    Eur J Immunol; 1997 Aug; 27(8):1988-93. PubMed ID: 9295036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of CD28 costimulation in immune-mediated responses against mouse mammary tumor viruses.
    Palmer LD; Saha B; Hodes RJ; Abe R
    J Immunol; 1996 Mar; 156(6):2112-8. PubMed ID: 8690899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alloreactive T cells that do not require TCR and CD8 coengagement are present in naive mice and contribute to graft rejection.
    Smith PA; Potter TA
    J Immunol; 1998 Jun; 160(11):5382-9. PubMed ID: 9605138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 4-1BB and OX40 act independently to facilitate robust CD8 and CD4 recall responses.
    Dawicki W; Bertram EM; Sharpe AH; Watts TH
    J Immunol; 2004 Nov; 173(10):5944-51. PubMed ID: 15528328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of treatment with IL-2 receptor specific monoclonal antibody in mice. Inhibition of cytotoxic T cell responses but not of T help.
    Leist TP; Kohler M; Eppler M; Zinkernagel RM
    J Immunol; 1989 Jul; 143(2):628-32. PubMed ID: 2544648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death.
    Hurtado JC; Kim YJ; Kwon BS
    J Immunol; 1997 Mar; 158(6):2600-9. PubMed ID: 9058792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.